Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform study of an innovative combination therapy in untreated recurrent or metastatic head and neck squamous cell carcinoma
CTR20244881Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zimberelimab, paclitaxel, carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Gilead Sciences. Started Dec 2024; status: terminated.
02
Drugs
zimberelimabpaclitaxelcarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20244881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244881.